STX3 (Syntaxin 3) encodes a member of the syntaxin family of SNARE (Soluble N-ethylmaleimide-sensitive factor Attachment protein Receptor) proteins essential for membrane fusion at the plasma membrane. STX3 is critically involved in synaptic vesicle exocytosis, neurotransmitter release, and polarized trafficking in neurons and epithelial cells[1]. Dysregulation of STX3-mediated fusion events has been implicated in the pathogenesis of Alzheimer's disease, Parkinson's disease, and various neurodevelopmental disorders[2][3].
| Syntaxin 3 | |
|---|---|
| Gene Symbol | STX3 |
| Full Name | Syntaxin 3 |
| Chromosome | 11q12.1 |
| NCBI Gene ID | [6809](https://www.ncbi.nlm.nih.gov/gene/6809) |
| OMIM | 600078 |
| Ensembl ID | ENSG00000166900 |
| UniProt ID | [Q99986](https://www.uniprot.org/uniprot/Q99986) |
| Associated Diseases | [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [Synaptic Dysfunction](/mechanisms/synaptic-dysfunction), Neurodevelopmental Disorders |
STX3 is a 289-amino acid type I membrane protein consisting of several functional domains:
The SNARE motif contains 16 layers of hydrophobic residues (a, d positions) that zipper together during SNARE complex formation, generating the force required for membrane fusion[1:1].
STX3 functions as a Q-SNARE (glutamine-containing SNARE) in the formation of ternary SNARE complexes:
The complete complex typically consists of:
This complex is regulated by multiple accessory proteins including:
The STX3 gene produces multiple splice variants with distinct tissue distributions:
STX3-mediated SNARE complex formation is critical for every step of the synaptic vesicle cycle[1:2]:
Beyond neurons, STX3 plays a critical role in polarized trafficking in epithelial cells[5]:
STX3 is expressed in astrocytes where it regulates[6]:
STX3 shows high expression in neurons throughout the brain:
| Brain Region | Expression Level | Cell Types |
|---|---|---|
| Hippocampus | Very High | CA1-CA3 pyramidal neurons, dentate gyrus granule cells |
| Cerebral Cortex | High | Layer 2/3 pyramidal neurons, interneurons |
| Cerebellum | Moderate | Purkinje cells, granule cells |
| Substantia nigra | High | Dopaminergic neurons (pars compacta) |
| Brainstem | Moderate | Motor nuclei, cranial nerve nuclei |
| Basal ganglia | High | Striatal medium spiny neurons |
STX3 dysfunction contributes to AD pathogenesis through multiple mechanisms[2:1][7][8]:
| Mechanism | Evidence | Impact |
|---|---|---|
| SNARE complex reduction | ↓ STX3 protein in AD brain (40-60%)[2:2] | Impaired neurotransmitter release |
| Aβ interaction | Aβ reduces STX3 expression in neurons[7:1] | Synaptic toxicity |
| LTP impairment | STX3 required for hippocampal LTP[4:1] | Memory deficits |
| Synaptic pathology | Altered SNARE stoichiometry in AD[2:3] | Memory consolidation failure |
Molecular cascade in AD:
STX3 is implicated in PD through dopaminergic neuron dysfunction[3:1][9][10]:
| Mechanism | Evidence | Impact |
|---|---|---|
| α-Synuclein interaction | α-Syn binds STX3 and disrupts SNARE complex[9:1] | Impaired dopamine release |
| SNARE alterations | ↓ STX3 in PD substantia nigra[3:2] | Dopaminergic degeneration |
| Genetic variants | STX3 promoter variants associated with PD risk[10:1] | Altered expression |
| Vesicle trafficking | Impaired vesicle cycling in PD models[3:3] | Synaptic dysfunction |
Molecular cascade in PD:
STX3 mutations cause a spectrum of neurodevelopmental disorders[11][12][13]:
| Disorder | STX3 Role | Phenotype |
|---|---|---|
| IDD (Intellectual Developmental Disorder) | Loss-of-function mutations | Intellectual disability, speech impairment |
| ASD (Autism Spectrum Disorder) | De novo missense mutations | Social deficits, repetitive behaviors |
| Epilepsy | Channel dysfunction | Seizure susceptibility |
| Cortical visual impairment | Polarized trafficking defects | Visual processing deficits |
Case study: A study of 12 patients with STX3 missense mutations showed:
Emerging evidence links STX3 to ALS:
STX3 represents a promising therapeutic target for neurodegenerative diseases:
| Approach | Status | Challenges |
|---|---|---|
| Gene therapy (AAV-STX3) | Preclinical | Delivery to appropriate neuronal populations |
| Small molecule SNARE stabilizers | Discovery | Specificity, blood-brain barrier |
| Antisense oligonucleotides | Discovery | Target delivery, off-target effects |
| Protein replacement | Preclinical | Stability, immunogenicity |
STX3 as a biomarker:
Band AM, et al. Syntaxin 3 in exocytosis. J Cell Biol. 1999. ↩︎ ↩︎ ↩︎
Hatano R, et al. Decreased SNARE proteins in Alzheimer's disease brain. Neurobiol Aging. 2013. ↩︎ ↩︎ ↩︎ ↩︎
Rodriguez L, et al. Synaptic SNARE complex alterations in Parkinson's disease. Brain. 2018. ↩︎ ↩︎ ↩︎ ↩︎
Lin WH, et al. Syntaxin 3 is required for long-term potentiation in hippocampus. Nat Neurosci. 2017. ↩︎ ↩︎
Kelley M, et al. Syntaxin 3 and polarized trafficking in epithelial cells. Dev Cell. 2018. ↩︎
Tomm M, et al. Syntaxin 3 in astrocyte-neuron metabolic coupling. Glia. 2019. ↩︎
Yang J, et al. STX3 regulates amyloid-beta induced synaptic dysfunction. J Neurosci. 2019. ↩︎ ↩︎
Wang L, et al. STX3 expression is downregulated in Alzheimer's disease brain. Acta Neuropathol. 2022. ↩︎
Chen X, et al. Alpha-synuclein interacts with STX3 and disrupts SNARE complex assembly. Cell Death Dis. 2020. ↩︎ ↩︎
Park J, et al. Syntaxin 3 promoter variants and risk for Parkinson's disease. Neurology. 2022. ↩︎ ↩︎
Ishikawa T, et al. Syntaxin 3 mutations linked to neurodevelopmental disorders. Nat Genet. 2012. ↩︎
Suzuki K, et al. STX3 mutations cause neurodevelopmental disorder with impaired speech. Am J Hum Genet. 2021. ↩︎ ↩︎
Nakanishi K, et al. STX3 deficiency leads to impaired neurotransmission and memory deficits. Mol Psychiatry. 2019. ↩︎